GlassScriptPhysician profile
Rachna Bhandari
NPI 1316235328
$52,951.48
in general payments reported to CMS, 2019-2025
35 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $1,688 · 2021: $5,546 · 2022: $2,692 · 2023: $5,402 · 2024: $10K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $12K · Consulting Fee: $2,000 · Travel and Lodging: $765 · Honoraria: $305 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,350.00 |
| Food and Beverage | $11,983.06 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $765.10 |
| Honoraria | $305.30 |
| Education | $281.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $29,146.08 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Journey Medical Corporation | $4,758.54 | 2020-2025 | |
| Abbvie INC. | $3,451.71 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Dermavant Sciences, INC. | $2,859.63 | 2022-2024 | Vtama |
| Genzyme Corporation | $1,416.35 | 2019-2025 | |
| Ucb, INC. | $1,264.87 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $1,160.36 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $900.16 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $583.46 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $578.21 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $562.59 | 2019-2025 | Klisyri, Seysara |
| Pfizer INC. | $553.56 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $530.66 | 2023-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $513.89 | 2019-2025 | |
| Merz North America, INC. | $504.62 | 2020-2025 | Xeomin |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $495.69 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $488.01 | 2023-2025 | Tremfya |
| Allergan, INC. | $467.41 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $412.84 | 2023-2025 | Jublia, Siliq, Cabtreo |
| Revance Therapeutics, INC. | $409.71 | 2024-2025 | Daxxify, Daxi |
| Vyne Pharmaceuticals INC. | $277.43 | 2020 | |
| Arcutis Biotherapeutics, INC. | $257.59 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $247.00 | 2025 | Anzupgo, Adbry |
| Organon LLC | $243.55 | 2025 | Vtama, Nexplanon |
| Aclaris Therapeutics, INC. | $179.71 | 2019 | |
| Amgen INC. | $167.54 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $157.00 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.64 | 2023-2025 | Spevigo |
| Epi Health, LLC | $63.89 | 2020-2022 | |
| Sebela Pharmaceuticals INC. | $35.10 | 2019 | |
| Celgene Corporation | $34.14 | 2019 | |
| Botanix Sb INC | $28.20 | 2025 | Sofdra |
| Encore Dermatology INC. | $26.16 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.08 | 2025 | |
| Mylan Pharmaceuticals INC. | $20.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachna Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.